Agenix has reported positive results of ThromboView study which evaluated the efficacy and accuracy in patients with suspected acute pulmonary embolism.
ThromboView is an imaging tool that uses antibodies to locate blood clots in the body.
The 52 patient multi-centre Phase II study is conducted by University of California San Diego Medical Center principal investigator Timothy Morris.
In the study the sensitivity and specificity of ThromboView for acute pulmonary embolism was compared to computed tomography (CT) scanning.
The researchers reported no adverse events and concluded that ThromboView was accurate, safe and well-tolerated in patients with a range of co-existing diseases in the chest and elsewhere.
ThromboView offers a test without exposing patients to contrast agents associated with CT pulmonary angiography.
Thromboview requires only a standard hospital gamma camera to take a single photon emission tomography (SPECT) image from which the reader can easily identify the presence, absence and location of a blood clot.
Thromboview has completed two US Food and Drug Administration (FDA) Phase II human clinical trials.